Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis

Pediatric Research

Volumn 79, Issue 2, 2016, Pages 295-300

  Woo, Martin ^a,b,c   Patterson, Eric K ^a   Cepinskas, Gediminas ^a,c   Clarson, Cheril ^a,b   Omatsu, Tatsushi ^a,c   Fraser, Douglas D ^a,b,c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

^c Centre for Critical   (Canada)

^d Translational Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; HEMOGLOBIN A1C; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; BIOLOGICAL MARKER; MMP2 PROTEIN, HUMAN; MMP8 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DISEASE SEVERITY; ENZYME RELEASE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE ADHERENCE; MALE; PRIORITY JOURNAL; ZYMOGRAPHY; BLOOD; COMPLICATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LEUKOCYTE; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

BIOMARKERS; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84982311553     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2015.215     Document Type: Article

References (42)

1. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet 2009; 373: 2027-33
2. Wolfsdorf J, Craig ME, Daneman D, et al. International Society for Pediatric and Adolescent Diabetes. Diabetic ketoacidosis. Pediatr Diabetes 2007; 8: 28-43
3. Sperling MA. Cerebral edema in diabetic ketoacidosis: an underestimated complication?. Pediatr Diabetes 2006; 7: 73-4
4. Close TE, Cepinskas G, Omatsu T, et al. Diabetic ketoacidosis elicits systemic inflammation associated with cerebrovascular endothelial cell dysfunction. Microcirculation 2013; 20: 534-43
5. Omatsu T, Cepinskas G, Clarson C, et al. Canadian Critical Care Translational Biology Group. CXCL1/CXCL8 (GRO?/IL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro. Am J Physiol Endocrinol Metab 2014; 306: E1077-84
6. Schmid-Schonbein GW. The damaging potential of leukocyte activation in the microcirculation. Angiology 1993; 44: 45-56
7. Vartak DG, Gemeinhart RA. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target 2007; 15: 1-20
8. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999; 65: 137-50
9. Yazdan-Ashoori P, Liaw P, Toltl L, et al. Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. J Crit Care 2011; 26: 556-65
10. Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J. The mechanisms of cerebral vascular dysfunction and neuroinflammation by MMP-mediated degradation of VEGFR-2 in alcohol ingestion. Arterioscler Thromb Vasc Biol 2012; 32: 1167-77
11. Stephan D, Sbai O, Wen J, et al. TWEAK/Fn14 pathway modulates properties of A human microvascular endothelial cell model of blood brain barrier. J Neuroinflammation 2013; 10: 9
12. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007; 50: 202-11
13. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, A novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-32
14. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007; 82: 1375-81
15. Hoffman WH, Stamatovic SM, Andjelkovic AV. Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res 2009; 1254: 138-48
16. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003; 5: 1317-27
17. Tester AM, Cox JH, Connor AR, et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One 2007; 2: e312
18. Schubert-Unkmeir A, Konrad C, Slanina H, Czapek F, Hebling S, Frosch M. Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: A role for MMP-8. PLoS Pathog 2010; 6: e1000874
19. Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998; 82: 923-30
20. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL2nd, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-64
21. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-9
22. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: A mechanism for regulating synthetic events. Blood 2011; 118: 1903-11
23. Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 2005; 78: 279-88
24. Liu W, Hendren J, Qin XJ, Shen J, Liu KJ. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 2009; 108: 811-20
25. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, et al. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003; 284: F671-9
26. Hein KD, King GL Vascular abnormalities in diabetes mellitus. In: Sowers JR, ed. Endocrinology of the Vasculature. New York: Springer, 1996: 135-44
27. Radomski A, Jurasz P, Sanders EJ, et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 2002; 137: 1330-8
28. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-Terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-Terminal domain in A similar manner to TIMP-2. J Biol Chem 1997; 272: 15496-500
29. Hernandez-Barrantes S, Toth M, Bernardo MM, et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 2000; 275: 12080-9
30. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008; 7: 85
31. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003; 270: 3739-49
32. Taraboletti G, D'Ascenzo S, Giusti I, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 2006; 8: 96-103
33. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992; 267: 11424-30
34. Marini S, Fasciglione GF, de Sanctis G, D'Alessio S, Politi V, Coletta M. Cleavage of bovine collagen I by neutrophil collagenase MMP-8. Effect of pH on the catalytic properties as compared to synthetic substrates. J Biol Chem 2000; 275: 18657-63
35. Razaq S, Wilkins RJ, Urban JP. The effect of extracellular pH on matrix turnover by cells of the bovine nucleus pulposus. Eur Spine J 2003; 12: 341-9
36. Tjaderhane L, Larjava H, Sorsa T, Uitto VJ, Larmas M, Salo T. The activation and function of host matrix metalloproteinases in dentin matrix breakdown in caries lesions. J Dent Res 1998; 77: 1622-9
37. Okada Y, Morodomi T, Enghild JJ, et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990; 194: 721-30
38. Varani J, Perone P, Fligiel SE, Fisher GJ, Voorhees JJ. Inhibition of type I procollagen production in photodamage: correlation between presence of high molecular weight collagen fragments and reduced procollagen synthesis. J Invest Dermatol 2002; 119: 122-9
39. Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res 2009; 43: 348-64
40. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002; 200: 561-74
41. Brisson AR, Matsui D, Rieder MJ, Fraser DD. Translational research in pediatrics: tissue sampling and biobanking. Pediatrics 2012; 129: 153-62
42. Gillio-Meina C, Cepinskas G, Cecchini EL, Fraser DD. Translational research in pediatrics II: blood collection, processing, shipping, and storage. Pediatrics 2013; 131: 754-66